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Effect of parathyroid hormone on human T cell activation. Lympho-
cytes have receptors for PTH and patients with chronic renal failure
have high blood levels of PTH and impaired lymphocyte function. It is
possible, therefore, that PTH affects lymphocyte function. We studied
the interaction between PTH and proliferation of human lymphocytes in
vitro and examined potential mechanisms for such an interaction. 1-84
PTH stimulated in a dose dependent manner PHA-induced proliferation
of T cells but had no effect on PWM-induced proliferation. The hor-
mone did not alter CD4/CD8 ratio. Inactivation of PTH abolished its
stimulatory effect. PTH augmented IL-2 production by PHA-activated
T cells but did not increase expression of IL-2R. 1-34 PTH also
stimulated PHA-induced T cell proliferation. TPA augmented PHA-
induced T cell proliferation but the addition of PTH to the culture
stimulated by PHA and TPA did not augment further the proliferation of
T cells. Staurosporin reversed the stimulation by PTH of the PHA-
induced lymphocyte proliferation. Both 1-34 and 1-84 PTH stimulated
cyclic AMP production by lymphocytes. Forskolin did not affect
PHA-induced T cell proliferation although it stimulated cyclic AMP
generation. The results show that: 1) PTH acts on T cells; 2) acute
exposure to PTH augments PHA-induced T cell proliferation and IL-2
production; 3) this action of PTH is related to its biological activity and
is most likely due to the ability of PTH to enhance entry of calcium into
cells and/or stimulation of protein kinase C but is independent of cyclic
AMP generation.
End-stage renal failure is associated with derangements in
cellular immunity [1—6]. The mechanisms of these abnormalities
are not clear. It has been postulated that factor(s) in the uremic
serum may participate in the genesis of the impaired cellular
response [7, 81.
Patients with chronic renal failure have secondary hyperpara-
thyroidism and elevated blood levels of parathyroid hormone
(PTH) [9—11]. Available data indicate that the excess PTH
affects the function of many organs in patients with uremia [12].
It is theoretically possible that PTH may also affect lymphocyte
function and play, at least in part, a role in the genesis of the
abnormalities of cellular immunity in uremia.
Several pieces of information lend a potential support for this
proposition. First, preliminary data of Hoette et al [13] sug-
gested that PTH may inhibit blastogenic response of lympho-
cytes to PHA. Also Shasha et al [141 also reported that both
human and bovine PTH significantly inhibited lectin-induced
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lymphocytes transformation. Second, several investigators re-
ported data consistent with the presence of PTH receptors in
human and bovine lymphocytes [15, 16]. Third, interleukin
(IL)2 which is produced by the T cells is important in the
proliferation and differentiation of the T and B lymphocytes
[17]. The production and/or secretion of IL-2 by T cells is
calcium dependent [18], and PTH through its ability to enhance
calcium entry into cells [19—231 may affect IL-2 production.
The present study was undertaken to examine the interaction
between intact PTH (1-84 PTH) and its aminoterminal fragment
(1-34 PTH) and lymphocytes from normal subjects, and to
investigate the mechanisms underlying such an interaction.
Methods
Normal healthy volunteers were studied. There were 11
females and 23 males. Their ages ranged between 23 to 39 (30
0.7) years. None were taking medications known to affect the
immune system or lymphocyte function.
Preparation of PBMC
Peripheral venous blood was drawn under sterile conditions
into vacutainers containing preservative-free heparin (GIBCO
Labs, Grand Island, New York, USA), 20 U per each 1.0 ml
blood. The blood was diluted with an equal volume of HBSS,
(Flow Laboratories, McLean, Virginia, USA) containing peni-
cillin (100 U/ml) and streptomycin (100 g/m1; GIBCO). Twenty
milliliters of diluted blood were layered on top of 15 ml of
Ficoll-Hypaque solution (Isolymph, Gallard-Schlesinger, New
York, USA), density 1.077 g/ml, in sterile 50 ml conical tubes
(Corning, New York, New York, USA). The samples were
centrifuged 30 minutes at 400 g at room temperature. PBMC (87
3% lymphocytes) were recovered from the plasma-isolymph
interface, washed twice with 50 ml of HBSS, and resuspended
in RPMI-1640 (GIBCO), supplemented with 10% heat-inacti-
vated fetal calf serum (FCS; Irvine Scientific, Irvine, California,
USA), penicillin 100 U/mI, streptomycin 100 .tgIml, and 2 mM
glutamine (GIBCO). Cell suspensions were adjusted to obtain a
final concentration of 2 X 106 PBMC/ml.
Proliferation assay
Except where noted otherwise, lymphocytes were cultured
for five days at 37°C in a humidified, water-jacketed incubator
(Forma Scientific, Marietta, Ohio, USA) in 5% CO2. The cells
were cultured at a density of 2 x 105/well in standard flat
bottom, 96 well microplates (Dynatech, Alexandria, Virginia,
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USA). Each well received 0.1 ml of cells in medium, either 0.1
ml of phytohemagglutinin (PHA), (reagent grade Wellcome
Diagnostics, Dartford, UK), or 0.1 of pokeweed mitogen
(PWM; GIBCO) and 0.05 ml of desired dilution of PTH in
medium. Mitogens were dissolved in culture medium and used
at a final concentration, of 1:450 vol/vol of the stock PHA and
1:250 vol/vol of the stock PWM. In cultures without PTH or
niitogen, desired amount of medium was added to reach the
final volume of 250 d.
The choice of the dilution of 1/450 vol/vol of the PHA stock,
the dose of 4 x 10 M 1-84 PTH and the duration of culture of
five days was based on preliminary studies. We evaluated the
PBMC response to varying dilutions of PHA (1/225 to 1/3600
vol/vol) both in the presence and absence of 1-84 PTH (1 x l0—
to 1 x 10 M). These preliminary studies revealed that the
dilution of 1/450 vol/vol PHA is suboptimal, that PTH stimu-
lated PHA-induced lymphocyte proliferation and the maximal
effect was noted at a concentration of 4 x l0— M. This
concentration of PTH exerted its stimulatory effect at dilutions
of PHA of 1/225, 1/450 and 1/900 vol/vol; however, the maximal
effect of PTH was noted at the suboptimal dilution of PHA
which was 1/450 vol/vol. We also found that this effect of PTH
on PHA-induced lymphocyte proliferation was variable during
the second and third days of culture. In these days PTH
modestly inhibited, had no effect or modestly stimulated lym-
phocyte proliferation. However, the stimulatory effect of PTH
was more consistent on day five of the culture.
After five days, the cultures were pulsed for four hours with
0.5 pCi of 3H-thymidine (Methyl-3H thymidine, specific activity
6.7 Ci/mmol, ICN Radiochemicals, Irvine, California, USA).
The cells were then harvested onto glass fiber filter paper using
an automated cell harvester (Cambridge Technology Inc., Cam-
bridge, Massachusetts, USA). The filters were dried overnight,
quenched in Betafluor (National Diagnostics, Manville, New
Jersey, USA) and counted in a liquid scintillation counter
(Model LS7000, Beckman Instruments, Palo Alto, California,
USA). Each determination was performed in four to six repli-
cates. The proliferation of lymphocytes is expressed as
thymidine uptake (counts per minute, CPM).
Preparations of PTH
Synthetic 1-34 bovine PTH was obtained from Bachem
(Torrance, California, USA). Bovine intact hormone (1-84
PTH) was purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA). In some experiments inactivated PTH was
used. The inactivation of the hormone was done as follows: the
PTH was dissolved in 0.2 ml of 0.1 m acetic acid adjusted to
the desired volume with 30% H202 and incubated at 37°C for
four hours; the reaction was stopped by rapid freezing at —70°C
and the product was recovered by lyophylization.
Production of IL-2 by cultured cells
Cultures were set as described earlier for the proliferation
assay except that 5% FCS was used, and 20 ms HEPES was
also added to the media. Cells were cultured with 1-84 PTH (4
x iO M) and PHA (1/450 vol/vol dilution) and with PHA alone
with triplicate for each group. At 48 hours of culture, superna-
tants from the replicates were collected, pooled into round
bottom microplates, and stored at —20°C until assayed. IL-2
was determined using a proliferative assay with an IL-2 depen-
dent murine CTLL cell line and recombinant human IL-2 as a
reference standard as previously described [241.
Expression of interleukin 2 receptors (IL-2R)
To determine the expression of IL-2R by lymphocytes,
PBMC were cultured in sterile tubes (Falcon, Division of
Becton Dickinson, Lincoln Park, New Jersey, USA) in RPMI-
1640 supplemented as previously described except that HEPES
(10 mM) was added. Cells were cultured at a density of 106 cells
per tube in a total volume of 1.25 ml. At 24, 48, and 72 hours,
cells were harvested, stained with a Phyco-Erythrin monoclo-
nal antibody to IL-2R (PE-IL2R, Becton Dickinson, Mountain
View, California, USA) and analyzed by flow cytometry using
a fluorescence activated cell sorter (Ortho System tp, Ortho-
diagnostic, Inc. Raritan, New Jersey, USA). Results are ex-
pressed as the percent of cells positive for the IL-2R.
IL-2 bound to lymphocytes under high affinity conditions was
evaluated (N = 3) as described by Robb, Greene and Rusk [25].
PBMC, 3 x i05, were incubated with 20 M to 200 M '251-IL-2
(NEN Products, Massachusetts, USA) for 10 minutes at 37°C.
Cell bound IL-2 was separated from excess lymphokine by
centrifugation at 10000 RPM through 200 p1 paraffin oil, and
both fractions were counted with a gamma counter. Control cell
aliquots were preincubated with 200 units of unlabeled recom-
binant IL-2 (Cetus Corp.). The percent bound 1251-IL-2 was
corrected for nonsaturable binding.
Effect of PTH on CD4/CD8 ratio
The CD4/CD8 ratios were determined on PBMC of normal
subjects before culture and after five days of unstimulated and
PHA-induced proliferation of lymphocytes with and without 4
x l0 M 1-84 PTH. For the determination of CD4/CD8 ratio,
two FITC conjugated monoclonal antibodies to T cell surface
antigens (Becton Dickinson) were used. These were anti-Leu 3
antibody, which reacts with the CD4 subpopulation and anti.
Leu 2 which reacts with the CD8 subpopulation. Pellets of
PMBC were incubated with 5 p1 monoclonal antibody, at 4°C
for 30 minutes. After washing the pellets, they were resus-
pended in 5% FCS complete RPMI medium and read on an
Ortho System 50 Cytoflow graph.
Effects of 12-0-tetradecanoyl phorbol 13-acetate (TPA) or
forskolin
These experiments were designed to examine the effects of
TPA alone and in the presence of PHA, 4 X l0 M 1-84 PTH
and PHA plus PTH on lymphocyte proliferation. TPA was
dissolved in DMSO and added to culture at a final TPA
concentration of 62 ng/ml. DMSO alone had no effect on
PHA-induced lymphocyte proliferation (PHA alone 36.1 X iO
2.9 X iO CPM vs. PHA plus DMSO 36.4 x i03 4.8 x l0
CPM). The effects of forskolin in the presence and absence of
PHA on lymphocyte proliferation were also examined. Thirty
microliters of forskolin solution (5 mg forskolin/l .0 ml of
ethanol) were added to 270 p1 of culture media, giving a final
concentration of 20 tg forskolin/ml. The studies with TPA and
forskolin were performed simultaneously.
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Effect of Staurosporin
The effect of 10—8 M Staurosporin, an inhibitor of protein
kinase C on the stimulatory effect of 1-84 PTH, on the PHA-
induced proliferation of lymphocytes was examined. Stauro-
sporin was dissolved in DMSO to prepare a stock solution of
10 M; culture media was then added to obtain a final concen-
tration of 10_8 M.
Effect of PTH on cyclic AMP production of PBMC
PBMC were isolated as described above, Two x 106 cells
were suspended in 1.0 ml Krebs-Ringer solution with 10 mM
HEPES, 2.8 mi D-glucose, 0.5 mg/mI BSA (pH 7.4). Twenty-
five microliters of either Krebs-Ringer, 1-34 PTH, 1-84 PTH or
forskolin solutions were added to 0.5 ml of cell suspension
giving a final concentration of 4 X io M of 1-34 and 1-84 PTH
and 20 .tg/ml of forskolin. The cells were incubated in a water
bath at 37°C for 30 minutes. The reaction was terminated by the
addition of 240 pJ of 10% perchioric acid, The mixture was then
neutralized with 180 d of 2 N potassium carbonate, diluted with
1.0 ml of distilled water and centrifuged at 3000 g for eight
minutes. The supernate was saved, the pellet was washed and
centrifuged twice and the supernate was saved after each
centrifugation. The pooled supernate was dried in an oven
(80°C) for 18 hours and then dissolved in 2 ml of the cyclic AMP
assay buffer. Cyclic AMP was measured utilizing the cyclic
AMP (1251) assay kit (Amersham Co., Arling Heights, Illinois,
USA).
Statistical analysis
All experiments were performed with paired controls. Stu-
dent's t-test was used for statistical analysis. P values below
0.05 were considered significant. Data are expressed as mean
1 SE.
Results
Effects of various PTH preparations on lymphocyte
proliferation
We first examined the effect of 1-84 PTH on unstimulated
lymphocyte cultures. The hormone produced a significant (P <
0.01) increase in lymphocyte proliferation as depicted by 3H-
thymidine uptake of 4.6 x l0 0.5 x io CPM compared to
that noted in unstimulated cultures without PTH (2.0 x l0
0,2 x io CPM).
We then examined the effect of PTH on PHA-induced lym-
phocyte proliferation. Figure 1 depicts the effects of increasing
doses of 1-84 PTH on PHA-induced lymphocyte proliferation
(N = 8). The hormone augmented the PHA-stimulated 3H-
thymidine uptake by PBMC in a dose dependent fashion.
Inactivation of the hormone (N 8) abolished its enhancing
effect on PHA-induced lymphocyte proliferation (Fig. 2). The
aminoterminal fragment of the hormone (1-34 PTH) also aug-
mented PHA-induced lymphocyte proliferation, but only at the
higher peptide concentration of 4 x iO M (Fig. 3), P <0.01 (N
= 8). Doubling the concentration of 1-34 PTH to 8 x l0 M did
not produce further stimulation. Moreover, the increase in the
PHA-induced lymphocyte proliferation by the 1-34 PTH (+28
5%) was significantly (P < 0.01) less than that produced by
equimolar concentration (4 x iO M) of 1-84 PTH (+51 9%).
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Fig. I. Effects of increasing concentrations of 1-84 PTH on PHA-
induced proliferation of human T cells. Each data point represents
mean value of 8 studies and the brackets denote I sa. *p < 0.01 from
data without PTH.
PTH had no effect on proliferation of lymphocytes stimulated
with PWM (Fig. 4).
Effect of PTH on IL-2 production
Since IL-2 is required for the sustainment of mitogen-induced
lymphocyte proliferation, we asked whether the PTH effect was
mediated by this lymphokine. Figure 5 depicts the effects of 4 x
i0 M 1-84 PTH on PHA-induced IL-2 production determined
after 48 hours of culture (N = 5). The mean IL-2 concentration
in the supernatants of cells cultured with PHA alone was 5.0
2.0 U/mI. The presence of PTH in culture media was associated
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Fig. 2. Effect of inactivated 1-84 PTH on PHA -induced human T cell
proliferation. Each column represents the mean value of 8 studies and
brackets denote 1 SE. < 0.01 versus PHA alone or PHA +
inactivated 1-84 PTH.
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Fig. 3. Effects of increasing concentrations of 1-34 PTH on PHA-
induced human T cell proliferation. Each column represents mean
value of 8 studies and brackets denote I SE. *D < 0.01 versus no PTH
or2 x 107M1-34PTH.
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Fig. 4. Effect of 1-84 PTH on PWM-induced T cell proliferation. Each
column represents mean value of 8 studies and brackets denote 1 SE.
with a significant (P < 0.01) increase in IL-2 concentration to
9.1 1.8 U/mI, Thus, 1-84 PTH had a significant stimulatory
effect on PHA-induced IL-2 production by PBMC. However, it
should be mentioned that 1-84 PTH did not cause a detectable
increase in IL-2 production by the unstimulated lymphocytes.
Effect of PTH on expression of IL-2R
Since mitogen-induced proliferation of lymphocytes requires
the expression of IL-2R on lymphocytes and since PTH aug-
mented PHA-induced lymphocyte proliferation, we examined
the effect of the hormone on expression of IL-2R. The IL-2R
were determined at 24, 48 and 72 hours in spontaneously
proliferating cells, in those stimulated with PHA alone, in cells
cultured with 4 x iO M 1-84 PTH alone, and in cells cultured
with both PHA and PTH (N = 4). The hormone alone did not
augment IL-2R by the unstimulated cells and did not alter their
expression on cells stimulated by PHA (Fig. 6). Table 1 depicts
the result of a representative experiment evaluating the expres-
sion of high affinity IL-2R on lymphocytes. PTH did not
augment the expression of these receptors.
Effect of TPA and forskolin on lymphocyte proliferation
Figure 7 depicts the effects of TPA and forskolin on lympho-
cyte proliferation (N = 10). TPA stimulated lymphocyte prolif-
eration to a degree not different from PHA (TPA: 37.8 X iO
6.2 x i03 CPM vs. PHA: 36.5 X iO 3.3 X iO CPM). TPA
significantly augmented the PHA-induced lymphocyte prolifer-
ation (PHA + TPA: 56.3 x 1O 5.7 x i0 CPM, P < 0.01).
The addition of 1-84 PTH to the cultures stimulated with PHA
and TPA did not augment further the lymphocyte proliferation
(PHA + TPA: 56.3 x iO 5.7 x iO CPM vs. PHA + TPA +
PTH: 57.2 x i0 6.1 x i03 CPM). Forskolin did not augment
PHA-induced lymphocyte proliferation (PHA: 36.5 X i0 3.3
x 10 CPM versus PHA + forskolin 41.5 x iO 4.3 X iO
CPM).
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Fig. S. Effect of 1-84 PTH (4 X 1O M) on PHA -induced IL-2 produc-
tion by human T cells after 48 hours of culture. Each column represents
mean value of 5 studies and brackets denote 1 SE. < 0.01.
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Fig. 6. Effect of unstimulated (U), 1-84 PTH (4 X io- M) alone (U),
PHA alone () and PHA + PTH (0) on IL-2R expression by human T
cells at various times of culture. Each column represents mean value of
4 studies and brackets denote I SE.
Table 1. Expression of high affinity IL-2R on lymphocytes
Hours
Specifically bound '251-IL-2%
Unstimulated PHA PTH PHA + PTH
24
48
72
0.8 0.4
0.9 0.4
1.6 1.0
0.4 0.3 0.9 0.4
2.6 0.5 0.9 0.4
6.8 1.7 1.7 0.7
1.1 0.5
2.3 0.2
6.3 0.8
Values indicated mean % '251-IL-2 specifically bound by 3 x
io lymphocytes after 24, 48, 72 hours of culture.
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Fig. 7. Effects of TPA (62 ng/ml) and forskolin (20 xg/ml) on PHA or
PHA + 1-84 PTH (4 x I0 M)-induced human T cell proliferation.
Symbols are: (0) unstimulated; (liii) PHA; (0) TPA; (0) PHA + PTH;(U) PHA + TPA; (D) PHA + TPA + PTH; ()forskolin;(•) forskolin
+ PHA. Each column represents mean value of 10 studies and brackets
denote 1 SE.
Effect of PTH on CD4ICD8 cells ratio
Table 2 reveals the data obtained in studies examining the
effect of 1-84 PTH on CD4ICD8 ratios. At time 0 of culture the
value of this ratio was 1.49 0.22, which is not different from
that reported by others [261. In the unstimulated culture, we
observed proliferation of the CD4 but not CD8 cells resulting in
Table 2.
cells aft
Effect of parathyroid hormone on percent C
er unstimulated or PHA-stimulated lymphoc
D4 and CD8
yte culture
PTH PHA
Preculture Unstimulated alone alone PTH + PHA
CD4%
CD8%
CD4/CD8
35.7 47.1 47.3 51.7
±3.2
25.5 27.6 24.la 43,9b
1.49 1.72 1.99a l.2lC
54.0
42.5a
1.35
a relative increase in CD4ICD8 ratio to 1.72 0.10. In the
presence of PTH alone, a similar effect was obtained, resulting
in an increase in CD4/CD8 ratio (1.99 0.11) which was
modestly but significantly (P < 0.02) higher than that observed
with unstimulated cultures. PHA induced proliferation of both
CD4 and CD8 cells with a greater effect on CD8 resulting in a
significant decrease in CD4ICD8 ratio as compared to unstim-
ulated cultures. 1-84 PTH did not alter the effect of PHA on
CD4ICD8 ratio.
Effect of Staurosporin
The data showed that this inhibitor of protein kinase C
reversed the stimulation by PTH of the PHA-induced lympho-
cyte proliferation (Table 3).
Effect of PTH on cyclic AMP
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Value shown are means SEM.
a P < 0.02 versus corresponding value during unstimulated cultureb P < 0.01 versus corresponding value during unstimulated culture
c P < 0.05 versus corresponding value during unstimulated culture
70
60
50 -
40 -
30 -
20 -
10 -
Both 1-34 and 1-84 PTH significantly stimulated cyclic AMP
production by PBMC (Fig. 8). The basal cyclic AMP level was
11.2 0.46 pmol/106 cells and increased to 19.1 3.2 pmol/106
(P < 0.05) with 1-34 PTH and to 26.3 5.2 pmoLIlO6 cells (P <
0.025) with 1-84 P'I'H. Similarly, forskolin significantly (P <
0.01) increased cyclic AMP generation by these cells (37.3 1.3
pmolllO6 cells).
Discussion
The results of the present study demonstrate that intact 1-84
PTH augmented PHA-induced lymphocyte proliferation in a
dose dependent manner. This effect of 1-84 PTH is related to its
biological activity and not to a contaminant of the hormone
preparation since inactivation of the hormone abolished its
effect. Further, the synthetic, pure, aminoterminal fragment,
(1-34 PTH) also augmented the PHA-induced lymphocyte pro-
liferation. In contrast PTH did not affect lymphocyte prolifer-
ation induced by PWM.
It is of interest that the 1-84 PTH was more potent than its
aminoterminal fragment in augmenting the PHA-induced lym-
phocyte proliferation. This is not surprising since previous
studies showed similar observations on the effect of these two
moieties of the hormone on isolated heart cells [27], on myo-
cardial bioenergetics [23] and on fatty acids oxidation by
skeletal muscle [28]. These observations suggest that other
parts of the PTH molecule besides the aminoterminal fragment
may have biological activity or that the intact molecule of the
hormone attaches more tightly to its receptor than does the
aminoterminal fragment.
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Table 3. Effect of Staurosporin on lymphocyte proliferation
No mitogen Staurosporin PHA PHA+PTH PHA+PTH+Staurosporin
3H-thymidine uptake (CPM x 10)
Study 1 2.4 0.5 5.4 1.5 42.5 3.9 65.6 9•7a 42.2 6.5
Study 2 3.0 0.2 3.5 1.0 46.3 0.8 71.7 0.2" 41.2 2.5
Data are presented as mean s. Each study is the mean of three measurements.
a P < 0.05 versus PHA, and PHA+PTH+Staurosporin
b p < 0.01 versus PHA, and PHA+PTH+Staurosporin
40
30
20
10
PHA is a T cell mitogen [17, 29, 30]. Since PTH augmented
PHA-induced lymphocyte proliferation and since the percents
of CD4 and CD8 cells noted during PHA and PTH stimulation
were not different from that with PHA alone, one can suggest
that the stimulatory effect of the hormone on lymphocyte
proliferation is due to an action on both CD4 and CD8 cells.
Available data indicate that both murine [31, 32], and human
[33] CD4 cells can be divided into at least two distinct subsets;
one type (Thi) responds to PHA to produce 1L2 and the other
type (Th2) responds to PWM to produce 1L4 [34]. Our finding
that PTH stimulated PHA and not PWM-induced cell prolifer-
ation and enhanced 1L2 production, suggest that the hormone
may stimulate proliferation of Thl subset of the CD4 cells.
Data suggesting an action of PTH on lymphocytes are lim-
ited. Whitfield, Mac Manns and Rixon [35] reported in 1970 that
PTH stimulated thymocyte (T cell) DNA synthesis. Perry [36]
found that 1-34 PTH activated mononuclear leukocytes, most
likely T cells, and caused them to produce a substance(s) that
enhances bone resorption. Others reported data consistent with
the presence of PTH receptors on lymphocytes [15, 16]. These
observations are in agreement with our results. Recently,
Atkinson et al [37] reported that 1-34 PTH and 1-38 PTH
stimulate proliferation of rat thymic lymphocytes. Thus, the
available data and our results demonstrate that T cells are a
target for PTH, and the hormone stimulates their proliferation.
It should be mentioned, however, that two studies reported that
PTH may inhibit the PHA-induced lymphocyte proliferation
[13, 14]. The data of Hoette et al [131 were preliminary; they
used Eli Lilly PTH extracts which contain a great deal of
impurities, the conditions of their culture (2% heated pooled
normal serum) were suboptimal and the duration of the culture
(2 days) was short. The studies of Shasha et al [14] used 1 x l0
cells per well and a three day culture compared to 2 x l0 cells
per well and five day culture in our study. These may provide
partial explanation for the differences between the two studies
since we also found that the effect of PTH on PHA-induced
lymphocyte proliferation is variable after two or three days of
culture. In addition, it is difficult to compare the amount of
hormone in our studies with those in the other two, since we do
not know how to convert mIU/ml concentration of their PTH
into molar concentrations of the hormone as used in our study.
The mechanisms underlying the effect of PTH on PHA-
induced proliferation may be complex. The proliferation of T
cells requires the presence of monocytes and their production
of IL- 1, production of IL-2 by T cells and the action of IL-2 on
its surface receptors on the lymphocytes [38—40]. It has been
shown that an increase in cytosolic calcium of T cells by a
calcium ionophore is associated with an increase in IL-2 pro-
duction and augmentation of lymphocytes proliferation induced
by suboptimal doses of PHA [17, 18]. Since PTH is known to
enhance calcium entry into many cells [19—23], it is reasonable
to suggest that the action of the hormone on T cell proliferation
is related to its ability to augment movement of calcium into
these cells and the consequent production of IL-2. Indeed, the
finding that PTH causes a significant increase in IL-2 produc-
tion in the presence of PHA is consistent with such a sequence
of events. Further support to this notion is found in the data of
Atkinson et al [37] showing that the action of PTH on prolifer-
ation of rat thymic lymphocytes depends on the presence of
calcium in the culture media and that the hormone causes a rise
in cytosolic calcium of these cells.
It is interesting that 1-84 PTH did not cause expression of
IL-2R in the unstimulated lymphocyte nor did it affect expres-
sion of IL-2R in PHA-treated cells. It appears, therefore, that a
potential PTH-induced movement of calcium into the T cells is
not associated with expression of IL-2R. This is not surprising
since it has been shown that a change in cytosolic calcium is not
required for induction of IL-2R [41]. One may speculate that
adequate number of expressed IL-2R induced by suboptimal
*
0 —
control 1-34 F'TH 1-84 PTH Forskolin
Fig. 8. Effect of vehicle, 4 x 1O M 1-34 and 1-84 PTH and of2O pg/mi
of forskolin on cyclic AMP production by lymphocytes. Each column
represents the mean of 3 studies (each measurement done in duplicate)
and the brackets denote 1 SE. < 0.05, < 0.025, ***p < 0.01
versus control.
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doses of PHA were available and permitted the enhancing effect
of PTH on T cell proliferation.
A PTH-induced calcium movement into T cells may also
stimulate lymphocyte proliferation independent of IL-2 produc-
tion. The hormone produced a modest but significant increase
in 3H-thymidine uptake in the unstimulated lymphocyte culture
without a detectable increase in IL-2 production. This observa-
tion is in agreement with data by Koretzky et al [42] who
demonstrated that A23 187 calcium ionophore can induce lym-
phocyte proliferation independent of IL-I and IL-2.
Several investigators have provided data consistent with the
presence of PTH receptors in the lymphocytes. Therefore,
PTH-PTH-receptor interactions may provide, at least, two
other pathways for the action of the hormone on the T cells.
First, PTH may stimulate an adenylate cyclase system in the
lymphocyte and generate cAMP which, in turn, may mediate
the effect of the hormone. Indeed, our data show that both 1-34
and 1-84 PTH stimulated cyclic AMP generation by PBMC.
However, this effect of PTH does not seem to be responsible for
its stimulation of PHA-induced T cell proliferation. First,
forskolin, an agent that stimulates adenylate cyclase activity
[43] did not augment PHA-induced lymphocyte proliferation in
our studies despite significant increase in cyclic AMP genera-
tion. Furthermore, others have found that forskolin, while
significantly increases cyclic AMP, inhibited mitogen-induced
lymphocyte proliferation [44]. Also Atkinson et al [37] found
that PTH-induced proliferation of rat thymic lymphocytes is
independent of cAMP,
Second, PTH- PTH-receptor interaction has been shown to
affect phospholipid turnover in many tissues [45—47]. Such an
effect would generate diacyiglycerol which is a potent stimulus
of protein kinase C. The increased activity of this enzyme may
augment the PHA-induced lymphocyte proliferation. Indeed,
our studies as well as those of others [44, 48] have demonstrated
that TPA, an agent that stimulates protein kinase C [49, 50]
augments PHA-induced lymphocyte proliferation. These obser-
vations and the finding in our study that PTH does not produce
further augmentation in PHA-induced lymphocytes prolifera-
tion in cultures with PHA and TPA is consistent with the notion
that action of PTH is mediated, at least in part, by an effect on
the activity of protein kinase C. Further support for this
postulate is provided by the reversal of the stimulatory effect of
PTH by staurosporin, an inhibitor of protein kinase C.
The clinical implications of the effects of PTH on T cell
function in the genesis of the abnormalities in cell immunity in
uremia need further investigation. We must emphasize that our
studies deal with the effect of acute exposure to PTH. I-low-
ever, in patients with advanced chronic renal failure, there is
chronic exposure to markedly elevated blood levels of PTH.
Such sustained exposure may result in a calcium overload of the
lymphocytes, down regulation of their PTH receptors and
altered phospholipid metabolism of their cell membrane. Either
or any combination of such events may have adverse effects on
lymphocyte function. Indeed, chronic exposure to PTH in renal
failure was associated with increased calcium content of many
organs [51—57] and down regulation of its receptors in bone [58].
Furthermore, many studies have demonstrated that the acute
effect of PTH may be different from its chronic action. For
example, excess amounts of PTH acutely stimulate the chro-
notropic [27] and inotropic [59] properties of the heart cells and
enhances random motility of polymorphonuclear leukocytes
[60], but chronic exposure to excess PTH decreases or stops the
beating of the heart cells [27], impairs the metabolism and
function of the heart [23] and reduces random motility of the
leukocytes [60].
In this context, Chatenoud et a! [61] reported the presence of
preactivated T cells in hemodialysis patients. This observation
could be, at least in part, due to the chronic exposure of the T
cells to high levels of PTH in these patients. Also Shasha et al
[62] found that the lectin-stimulated lymphocyte transformation
was significantly reduced in three patients with primary hyper-
parathyroidism, and this abnormality was corrected one month
after the removal of the parathyroid adenoma. These data
further support the notion that chronic exposure of the T cells
to excess PTH may affect their function.
We would like to mention that the PTH dose in our in vitro
studies demonstrating a direct effect of the hormone on the T
cells is high and even exceeds the high blood levels of PTH in
patients with chronic renal failure. This may raise the question
about the physiological significance of this action of the hor-
mone. However, we would like to emphasize that the in vitro
dose of PTH required to elicit most of the non-traditional effects
of PTH such as those on the heart cells [27], hematopoietic cells
[63], red blood cells [221, white blood cells [60, 64], pancreatic
islets [65] and vascular smooth muscle [66] are also high.
Several possibilities should be considered to explain this phe-
nomenon as discussed in detail by Potts [67]. First, these
non-traditional actions of PTH could be non-specific and do not
represent hormone-receptor interaction. However, in many of
these studies including the present one, PTH stimulated cyclic
AMP production [27, 65], suggesting the presence of receptors
responsive to PTH in many of these cells. Second, the non-
traditional actions of PTH are mediated by stimulation of cell
receptors that are responsive to other agonists. This implies
that PTH acts as a "surrogate for the normally active agonist"
[67]. If this postulate is correct, one might expect that different
regions of the PTH molecule other than those involved in
mediating the mineral action of the hormone would be respon-
sible for the non-traditional effects. Indeed, in many studies,
1-34 PTH, considered to be the biologically active fragment for
mediating the mineral actions, does not elicit the non-traditional
effects [60, 63, 64]. If PTH mediates these latter actions as a
surrogate for other agonist, one would expect that higher doses
of PTH are needed. Third, it is also possible that the non-
traditional actions of PTH are mediated by activation of specific
receptors that may or may not be related to the PTH receptors
responsible for the mineral actions of the hormone. Such
potential PTH receptors responsible for its non-traditional
actions may be present at low concentration and may require
higher doses of the hormone for their activation. Finally, the in
vitro cell preparation may contain cell components, such as
proteases, which may degrade the hormone, and hence higher
quantities are required to elicit its action.
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